Pediatric Pharmacotherapy8

Download as pdf or txt
Download as pdf or txt
You are on page 1of 1

CHAPTER 28

AUTISM SPECTRUM DISORDERS Jose A. Rey, Pharm.D., M.S., BCPP

otherwise specified (PDD-NOS) (Reference 1). Autism


LEARNING OBJECTIVES spectrum disorders (ASDs) are a subset of PDDs that
1. Explain the clinical presentation and diagnostic include autistic disorder, Asperger’s disorder, and PDD-
criteria for autism spectrum disorder (ASD). NOS (see Figure 1). This chapter will focus on autistic
2. Discuss the application and efficacy of disorder as the predominant ASD.
pharmacotherapeutic interventions for symptom- In 1943, Dr. Kanner described children who with-
specific treatment and the limitations of drew, disregarded people, avoided eye contact, lacked
pharmacotherapy in ASD. social awareness, had limited language, displayed ste-
3. Recommend and monitor pharmacotherapy for reotyped motor movements, and showed a preservation
ASD for therapeutic outcomes and adverse drug of sameness as having a disorder called early infantile
effects, together with considerations of possible autism (References 2, 3). At the time, Dr. Kanner pro-
comorbid conditions. posed that autism resulted from an inborn inability to
form loving relationships with other people and de-
ABBREVIATIONS IN THIS CHAPTER scribed the parents of these children as cold and de-
tached. Today, although the general behavioral descrip-
ABC-I Aberrant Behavior Checklist— tion of the disorder has not changed significantly, the
Irritability subscale proposed causes of autism are now believed to be more
ADHD Attention-deficit/hyperactivity neurobiologic in etiology, though they are still not de-
disorder finitively known (Reference 3).
ASD Autism spectrum disorder The most significant clinical features of a child with
CARS Childhood Autism Rating Scale
an ASD often include qualitative impairments in the
CGI Clinical Global Impression Scale
major domains of (1) social interaction or reciprocity,
DSM Diagnostic and Statistical Manual
(2) communication and language, and (3) repetitive,
for Mental Disorders
restricted, or stereotypic behaviors. Other problematic
EPS Extrapyramidal symptoms
IDEA Individuals with Disabilities and maladaptive behaviors that may prompt the use
Education Act of pharmacotherapy include irritability, tantrums, ag-
OCD Obsessive-compulsive disorder gression, and attention-deficit/hyperactivity symptoms
PANDAS Pediatric autoimmune neuro- (Reference 1).
psychiatric disorders associated
with streptococcal infection EPIDEMIOLOGY
PDD Pervasive developmental disorder
PDD-NOS Pervasive developmental disorder– The prevalence of ASDs has been a matter of debate in
not otherwise specified recent years. Some estimate the numbers to be 1 or 2
SSRI Selective serotonin reuptake per 1000, whereas other reports estimate the prevalence
inhibitor to be as high as 1 or 2 per 100 (References 4–12). The
average is reported to be 6 or 7 per 1000 children for
the three ASDs combined (Reference 8). It is thought
that the increased prevalence of ASDs is because of the
INTRODUCTION increase in awareness through media coverage and the
Pervasive developmental disorders (PDDs) often present application of diagnostic criteria (Reference 8). Crite-
considerable problems and challenges for patients, fami- ria for infantile autism were provided in the DSM-III,
lies, caregivers, and health care providers. The five PDDs but the criteria have changed through the years, which
recognized in the Diagnostic and Statistical Manual for may have affected how the disorder is identified. An-
Mental Disorders (DSM-IV-TR) are Asperger’s disorder, other event that may have affected the diagnosis rate of
autistic disorder, childhood disintegrative disorder, Rett’s ASDs is the passage of the Individuals with Disabilities
disorder, and pervasive developmental disorder-not Education Act (IDEA) in 1990 (Reference 8). With

Autism Spectrum Disorders ƒ Rey ƒ 409

You might also like